Related Experiment Video

Updated: Aug 19, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Anti-inflammatory strategies in hypertension: focus on COX-1 and COX-2

Matthias Hermann1, Frank Enseleit, Frank T Ruschitzka

  • 1Cardiology, University Hospital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland.

Current Hypertension Reports
|February 3, 2005
PubMed

Insights

High blood pressure may cause inflammation, increasing cardiovascular risk. Targeting blood pressure and inflammation, possibly via cyclooxygenase-1 and -2, could benefit patients.

Area of Science:

  • Cardiovascular Science
  • Inflammation Biology
  • Pharmacology

Background:

  • Elevated blood pressure is linked to a proinflammatory response.
  • C-reactive protein and blood pressure are independent cardiovascular risk factors.
  • Combined, these factors have enhanced predictive value for cardiovascular events.

Purpose of the Study:

  • To review the role of chronic low-grade inflammation in cardiovascular disease.
  • To explore the involvement of cyclooxygenase-1 and -2 in inflammation.
  • To discuss potential anti-inflammatory treatment strategies.

Main Methods:

  • Literature review of existing studies on blood pressure, inflammation, and cardiovascular risk.
  • Analysis of the mechanisms linking inflammation and hypertension.
  • Examination of the role of cyclooxygenase enzymes in inflammatory pathways.

Main Results:

  • Evidence suggests a direct link between elevated blood pressure and inflammation.
  • Cyclooxygenase-1 and -2 are implicated in the inflammatory processes associated with cardiovascular disease.
  • Combined assessment of blood pressure and C-reactive protein improves cardiovascular risk prediction.

Conclusions:

  • Strategies to lower blood pressure and reduce vascular inflammation may offer clinical benefits.
  • Targeting cyclooxygenase-1 and -2 represents a potential therapeutic avenue for cardiovascular disease.
  • Understanding the interplay between hypertension and inflammation is crucial for developing effective treatments.

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...